Literature DB >> 26787557

Validity and power considerations on hypothesis testing under minimization.

Zhenzhen Xu1, Michael Proschan2, Shiowjen Lee1.   

Abstract

Minimization, a dynamic allocation method, is gaining popularity especially in cancer clinical trials. Aiming to achieve balance on all important prognostic factors simultaneously, this procedure can lead to a substantial reduction in covariate imbalance compared with conventional randomization in small clinical trials. While minimization has generated enthusiasm, some controversy exists over the proper analysis of such a trial. Critics argue that standard testing methods that do not account for the dynamic allocation algorithm can lead to invalid statistical inference. Acknowledging this limitation, the International Conference on Harmonization E9 guideline suggests that 'the complexity of the logistics and potential impact on analyses be carefully evaluated when considering dynamic allocation'. In this article, we investigate the proper analysis approaches to inference in a minimization design for both continuous and time-to-event endpoints and evaluate the validity and power of these approaches under a variety of scenarios both theoretically and empirically. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  analyze as you randomize; covariate adaptive randomization; dynamic allocation; minimization; permutation test; power; randomization; re-randomization test; temporal trend; validity

Mesh:

Year:  2016        PMID: 26787557     DOI: 10.1002/sim.6874

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Impact of minimal sufficient balance, minimization, and stratified permuted blocks on bias and power in the estimation of treatment effect in sequential clinical trials with a binary endpoint.

Authors:  Steven D Lauzon; Wenle Zhao; Paul J Nietert; Jody D Ciolino; Michael D Hill; Viswanathan Ramakrishnan
Journal:  Stat Methods Med Res       Date:  2021-11-29       Impact factor: 2.494

2.  Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials.

Authors:  Giulia Manzini; Doris Henne-Bruns; Michael Kremer
Journal:  BMJ Open Gastroenterol       Date:  2017-09-14

3.  Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.

Authors:  Etsuro Nanishi; Hisanori Nishio; Hidetoshi Takada; Kenichiro Yamamura; Mitsuharu Fukazawa; Kenji Furuno; Yumi Mizuno; Kenjiro Saigo; Ryo Kadoya; Noriko Ohbuchi; Yasuhiro Onoe; Hironori Yamashita; Hideki Nakayama; Takuya Hara; Takuro Ohno; Yasuhiko Takahashi; Ken Hatae; Tatsuo Harada; Takayuki Shimose; Junji Kishimoto; Shouichi Ohga; Toshiro Hara
Journal:  J Am Heart Assoc       Date:  2017-07-06       Impact factor: 5.501

4.  Acupuncture for cancer pain: protocol for a pilot pragmatic randomised controlled trial.

Authors:  Yihan He; Brian H May; Anthony Lin Zhang; Xinfeng Guo; Yihong Liu; Yanchun Qu; Xuesong Chang; Chuan-Jian Lu; Charlie Changli Xue; Haibo Zhang
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

5.  Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials.

Authors:  Giulia Manzini; Ursula Klotz; Doris Henne-Bruns; Michael Kremer
Journal:  World J Gastrointest Oncol       Date:  2020-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.